Valuation: Memphasys Limited

Market Cap 20.07M 13.98M 12.29M 11.41M 10.49M 19.68M 1.35B 136M 53.22M 661M 52.47M 51.34M 2.29B P/E 2024
-2.18x
P/E 2025 -1.57x
Enterprise Value 24.97M 17.4M 15.29M 14.2M 13.05M 24.5M 1.68B 170M 66.23M 823M 65.3M 63.89M 2.85B EV / Sales 2024
13,037,852x
EV / Sales 2025 24,365,123x
Free-Float
70.43%
Yield 2024 *
-
Yield 2025 -
1 day+14.29%
Current month+23.08%
1 month+33.33%
3 months+45.45%
6 months+33.33%
Current year+14.29%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.006
0.01
Current year 0
Extreme 0.004
0.01
1 year 0
Extreme 0.003
0.01
3 years 0
Extreme 0.003
0.02
5 years 0
Extreme 0.003
0.12
10 years 0
Extreme 0.003
0.16
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 2021-06-30
Corporate Secretary - 2025-10-07
Director TitleAgeSince
Director/Board Member - 2018-06-06
Director/Board Member - 2025-10-19
Chairman - 2026-05-18
Date Insider Type Main position Quantity % Market Cap.
1/2/23 Buy

Director

1,400,000 0.1459%
1/2/23 Buy

Chief Executive Officer

392,500 0.0409%
1/24/22 Sell

Director

1,350,000 0.1704%
Change 5-day change 1-year change 3-year change Capi.($)
+14.29%0.00%+60.00%-46.67% 15.12M
+8.71%+6.92%+33.84%+1.80% 196B
+7.46%-4.13%+1.36%-24.77% 126B
-2.54%-14.64%-35.03%-1.38% 120B
+1.42%+1.25%-57.75%-18.02% 63.87B
-0.65%-3.95%+9.86%-9.45% 48.58B
-1.56%-2.07%-25.50%-33.72% 43.93B
+4.71%+3.73%+20.27%+9.50% 37.69B
+3.13%+2.00%+33.03%+32.45% 36.41B
+3.14%+5.19%+92.94%+3.34% 28.88B
Average +3.41%-4.30%+13.30%-8.69% 70.13B
Weighted average by Cap. +3.12%-4.99%+4.13%-6.26%

Financials

2024 2025
Net sales 1.09 0.76 0.67 0.62 0.57 1.07 73.31 7.41 2.89 35.91 2.85 2.79 124.39 0.53 0.37 0.32 0.3 0.28 0.52 35.45 3.58 1.4 17.36 1.38 1.35 60.14
Net income -4.44M -3.09M -2.72M -2.53M -2.32M -4.36M -299M -30.19M -11.78M -146M -11.62M -11.37M -507M -5.04M -3.51M -3.08M -2.87M -2.63M -4.94M -339M -34.25M -13.36M -166M -13.18M -12.89M -575M
Net Debt 4.53M 3.16M 2.77M 2.58M 2.37M 4.45M 305M 30.8M 12.02M 149M 11.85M 11.59M 517M 4.9M 3.42M 3M 2.79M 2.56M 4.81M 330M 33.33M 13.01M 162M 12.82M 12.55M 560M
Logo Memphasys Limited
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Employees
24
Date Price Change Volume
26-07-23 A$0.008000 +14.29% 3,941,766
26-07-22 A$0.007000 -12.50% 143,020
26-07-21 A$0.008000 0.00% 465,549
26-07-20 A$0.008000 0.00% 4,479,952
26-07-17 A$0.008000 0.00% 5,240,884